Lanean...
Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer
Nivolumab is a PD-1 inhibitor approved for the use in treatment of multiple tumor types (such as melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial cancer and Hodgkin’s lymphoma). In July 2017, the US FDA granted accelerated approval of this agent for the treatment of metastatic...
Gorde:
| Argitaratua izan da: | Future Oncol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Future Medicine Ltd
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088272/ https://ncbi.nlm.nih.gov/pubmed/29473436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2017-0696 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|